Latest News and Promotions
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
Take2 Health Settled in Qianhai Kerry Centre, Shenzhen, Laying the Foundation for Business Expansion
In pursuit of following the prudent strategies for long-term business development, Take2 Health has officially settled in Qianhai Kerry Centre, Shenzhen, in 2021 year-end.
Take2 Health was Recognised as the Rising Star Company by Deloitte Hong Kong
Take2 Health was honoured to be named the Rising Star Company in the 2021 Deloitte Hong Kong Technology Fast 20 (#TF20) program on Dec 15, 2021.
Joining Hands with PwC, to Provide Early Cancer Detection Test via Employee Benefit Platform
Take2 Health has reached a collaboration with PwC that starting from 2 December 2021, PwC employees can enjoy the privileged price for taking the Take2 Prophecy™ Test for Nasopharyngeal Cancer in designated medical service providers through their corporate welfare platform PwC Wellness Reimagined.
Collaborating with GMT, Take2 Prophecy™ is Currently Available Across the Philippines
Take2 Health and Global Medical Technologies collaborate on the distribution of the Take2 Prophecy™ Test for Nasopharyngeal Cancer in the Philippines.
Take2 Health Invites Eric Cheung to Explain His Cancer Survival Story
Hong Kong-based healthcare tech startup Take2 Health has launched a campaign to introduce a product for nasopharynx cancer testing and is featuring actor Eric Cheung Tat-ming, who is also a survivor of the cancer.
Take2 Health Collaborating with CXA to Provide Innovative Employee Benefits
Starting from November 2020, the Take2 Prophecy™ Test for Nasopharyngeal Cancer and other health assessment services officially joined the CXA’s wellness provider network, providing the innovative medical solution to Hong Kong users.
Take2 Health 2021 Latest Campaign - Go Live Again
Mr. Cheung Tat-ming, a Nasopharyngeal Cancer (NPC) survivor, had experienced a delay in seeking medical intervention because of lacking cancer awareness, and hence he overlooked the warning signs of his health. Through his story, he is sharing with everyone his thoughts on the importance of detecting cancer early. According to the World Health Organization statistics of 2018, the NPC incidence rate in Hong Kong is 5 to 6 times the world’s average1,2. We should all be reminded not to overlook the risk of NPC. It can strike anyone at any age. Therefore, everyone must be vigilant to NPC and consider taking the early NPC detection test as a precaution.
Take2 Health and KPMG Reached Partnership to Enlist the Take2 Prophecy™ as Employee Benefit
From 1 October 2021 onwards, KPMG employees could choose the Take2 Prophecy™ Test for Nasopharyngeal Cancer and be eligible for reimbursement under their employees’ medical check-up benefit.
Partnered with HK Federation of Insurers to Share Non-invasive Early Cancer Detection Technology
Supported by the Hong Kong Federation of Insurers, an industry sharing themed “Screening for Early Cancers by Circulating DNA Analysis”, was successfully held on 17 September 2021.
Take2 Health is Honoured to be Awarded in the 2021 Inaugural SportsHour Company Scheme
Take2 Health is honoured to receive the Inaugural SportsHour Company Scheme Award which is organised by the InspiringHK Sports Foundation.
Take2 Health Partnering with Pascific Laboratories to Offer Early Cancer Detection Test
Take2 Health and Pascific Laboratories are working together to offer the Take2 Prophecy™ Test for Nasopharyngeal Cancer in the Philippines, as the first step of rolling out the operation.
Take2 Health Partnering with LifeStrands Genomics to Serve Singapore, Malaysia, and Vietnam
Take2 Health and LifeStrands Genomics Pte. Ltd, a diagnostic service subsidiary wholly owned by the Pathology Asia Holdings Pte. Ltd, have jointly announced a partnership to distribute the Take2 Prophecy™ Test for Nasopharyngeal Cancer.
Take2 Prophecy™ is Now Serving More than 20,000 Employees Upon Launching on HSBC Life Benefits+
Since March 2021, the Take2 Prophecy™ Test for Nasopharyngeal Cancer and related health assessment services are available on HSBC Life Benefits+ as one of the new employee benefits.
Take2 Health Teaming Up with Yourgene Health to Expand its Service to Taiwan Region
Take2 Health and Yourgene Health have reached a partnership to offer the clinically-validated Take2 Prophecy™ Test for Nasopharyngeal Cancer in Taiwan region, as well as to establish a medical network for the collection of clinical specimens.
Take2 Health and Pantai Premier Pathology Joining Hands to Promote Early NPC Detection
Take2 Health and Pantai Premier Pathology joined hands to offer the Take2 Prophecy™ Test for Nasopharyngeal Cancer in Malaysia, aiming to identify early-stage NPC patients and thereby enable timely diagnosis and treatments for patients in Malaysia.